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A B S T R A C T
Driver oncogenes are prime targets for therapy in tumors many of which, including leukemias and sarcomas,
express recurrent fusion transcription factors. One speciﬁc example for such a cancer type is alveolar rhabdo-
myosarcoma, which is associated in the majority of cases with the fusion protein PAX3-FOXO1. Since fusion
transcription factors are challenging targets for development of small molecule inhibitors, indirect inhibitory
strategies for this type of oncogenes represent a more promising approach. One can envision strategies at dif-
ferent molecular levels including upstream modiﬁers and activators, epigenetic and transcriptional co-reg-
ulators, and downstream eﬀector targets.
In this review, we will discuss the current knowledge regarding potential therapeutic targets that might
contribute to indirect interference with PAX3-FOXO1 activity in alveolar rhabdomyosarcoma at the diﬀerent
molecular levels and extrapolate these ﬁndings to fusion transcription factors in general.
1. Introduction
Targeted therapies are generally believed to have the potential to
revolutionize cancer therapy. Optimally, targeted drugs should aﬀect
cancer and spare normal cells in the body, thereby greatly enlarging the
therapeutic window over currently used chemotherapy-based ap-
proaches. Prime targets for such drugs are altered (mutated or over-
expressed) driver oncogenes present in a given tumor. Some of them are
frequently expressed, such as EGFR mutations in non-small-cell-lung
cancer (NSCLC) or mutant BRAF in melanoma, while other potentially
actionable targets are expressed in a minority of patients or even in
single individuals only. Analysis of the mutational landscape by next
generation sequencing (NGS), as already implemented in the clinics for
some entities, allows identiﬁcation of such targets and helps to tailor
patient speciﬁc therapies with targeted drugs [1]. However, in some
tumor types, actionable targets are not (or only in rare cases) available
and therefore this strategy is less helpful. Examples are several pediatric
malignancies such as leukemia and sarcoma, which are associated with
speciﬁc chromosomal translocations, generating fusion oncogenes. Ty-
pically, these are characterized by a simple, near-diploid karyotype and
a very low mutational burden. In a surprisingly large number of cases,
the translocations are the only cancer-associated aberrations identiﬁ-
able, even by whole genome sequencing [2]. Moreover, clonal analyses
revealed that other mutations, if present, are secondary to the trans-
location event and might therefore be expressed only in subsets of
tumor cells [3]. Taken together, this demonstrates that the fusion
proteins act as main drivers of tumorigenesis. Importantly, genetic loss-
of-function studies in diﬀerent cancers revealed that tumor cells are
addicted to the activity of the fusion proteins and undergo cell death
when they are depleted [4–6]. These results suggest that they are
among the most promising targets for successful therapy.
Strikingly, only a minority of the known fusion proteins contain a
druggable domain, such as kinase-domains present in BCR-ABL in
chronic myelogenous leukemia (CML), or in ALK and NTRK transloca-
tions both found in diﬀerent carcinoma, haematologic tumors, and
sarcoma [7,8]. The great clinical success in treatment of CML patients
with BCR-ABL inhibitors, but also the promising preliminary clinical
experience with ALK and NTRK inhibitors [8–13], underscores the
suitability and importance of fusion oncogenes as therapeutic targets in
general. However, the great majority of fusion proteins act as tran-
scription factors (TF) and are composed of domains from two TFs,
transcriptional co-regulators or other types of non-enzymatic proteins.
From a molecular perspective, such fusion proteins are challenging
targets for inhibitor development. Traditional drugs belong either to the
group of biologics including antibodies, peptides, nucleic acids or
vaccines or to the group of small molecules [14]. While the former are
only suitable to target cell surface or secreted proteins, the latter are
designed to bind into deep hydrophobic pockets of proteins, such as the
enzymatic cleft of enzymes. Hence, both classes of drugs are less sui-
table for TFs, as well as many other proteins, which are intracellularly
located and mediate their physiological function via protein-DNA and
protein–protein interaction. Interaction surfaces are normally large and
unaﬀected by conventional small molecule inhibitors. Furthermore,
with the exception of the DNA binding domains, large parts of TFs are
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often intrinsically disordered and hence their 3D structure is labile and
dependent on interactions with functional partners [15]. Based on this
low druggability, direct inhibition of TFs was claimed to be very diﬃ-
cult. This fact is also exempliﬁed by the decades-long, but so far un-
fruitful eﬀorts to identify drugs that would directly inhibit the oncogene
c-MYC [16]. Furthermore, experimental approaches including mRNA
targeting using nucleic acid based therapeutics (antisense oligonu-
cleotide or siRNA) that work well in in vitro model systems [17,18],
might not be easily translatable to the clinics. However, activation or
repression of target gene transcription does not only depend on the
fusion TF itself, rather these proteins act in concert with many other
proteins, including epigenetic regulators as well as the basic tran-
scriptional machinery. At this level, one might be able to identify
druggable targets amenable for indirect interference with TF activity. In
addition, also synthesis and degradation pathways, as well as potential
activation steps by post-translational modiﬁcations and/or relevant,
selected downstream targets might represent potential levels for in-
hibition (Fig. 1). Hence, we argue that a deeper understanding of the
biology of the individual fusion proteins might lead to identiﬁcation of
novel therapeutic targets.
2. FOXO translocations in alveolar rhabdomyosarcoma
Several members of the FOXO family are involved in translocations
leading to generation of oncogenic fusion TFs. These include MLL-
FOXO3/4 found in leukemias and PAX-FOXO1/4 fusions found both in
sinonasal sarcoma and alveolar rhabdomyosarcoma (aRMS) [19–24]. In
all cases the C-terminal transactivation domain of the FOXO protein is
fused to the N-terminal DNA binding domain of the fusion partner. The
resulting fusion protein acts as highly active TF inducing aberrant ex-
pression of target genes of the DNA-binding partner protein. One of the
best studied among these fusion proteins is PAX3-FOXO1 in aRMS and
therefore development of therapies based on functional knowledge of
its biology might serve as blueprint for other fusion TFs.
aRMS belongs to the group of rhabdomyosarcoma (RMS) which are
the most common soft tissue sarcoma in children accounting for 3% of
all childhood and 2% of all adolescent cancers [25]. According to the
latest WHO classiﬁcation, RMS includes the subtypes alveolar (aRMS),
embryonal (eRMS), spindle cell/sclerosing (sRMS/scRMS) and pleo-
morphic RMS (pRMS). While all these tumors are characterized by
myogenic features, the diﬀerent subgroups are clearly distinct by his-
tological, molecular and clinicopathological characteristics.
Current therapy of RMS is still based on conventional strategies
including chemotherapy, surgery and radiotherapy. While in some
subgroups such as eRMS, application of these therapies increased the 5-
year overall survival to more than 70%, eﬃcacy in other subgroups is
still much lower and 5-year overall survival remains dismal (< 50%)
[26]. Especially in case of aRMS, novel therapeutics are urgently
needed.
60% of aRMS cases bear PAX3-FOXO1 fusion proteins and a
homologous fusion PAX7-FOXO1 is detected in another 20%, while
alternative fusions of PAX3 with FOXO4, NCOA1/2, Gli2, INO80 have
been found in a smaller number of cases [2,24,27–29]. The corre-
sponding wildtype proteins have been intensely studied in the past. The
PAX family TFs (PAX1-9) act as regulators of lineage commitment and
tissue development during embryogenesis [30]. PAX3 is involved in
regulation of neural tube, neural crest and skeletal muscle develop-
ment.
The main physiological role of the FOXO family of TFs (FOXO1,
FOXO3, FOXO4 and FOXO6) is the induction of an adequate response to
environmental changes to maintain homeostasis [31]. Under homeo-
static conditions, FOXO TFs are transcriptionally inactivated by se-
questration into the cytoplasm. A range of posttranslational modiﬁca-
tions (phosphorylation, acetylation) are involved in induction of
nuclear export. Diﬀerent types of environmental stresses lead to nuclear
translocation of FOXO proteins. This major activation step then initiates
the transcription of target genes, which aﬀect diﬀerent cellular pro-
cesses including cell cycle, cell survival and metabolism. In sum, this
helps the cell to adapt to the new conditions [31].
The PAX3-FOXO1 fusion protein is composed of two N-terminal
Fig. 1. Scheme depicting the diﬀerent molecular levels potentially amenable for indirect targeting of fusion TFs using the example of PAX3-FOXO1. Proteins depicted in red are relevant
for PAX3-FOXO1 activity in aRMS and are discussed in the text. Inhibitors and agonists discussed in the text are depicted in blue. PD, paired domain; HD, homeodomain; M, modiﬁcation.
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DNA binding domains of PAX3 (paired box domain and paired-type
homeodomain) and the C-terminal transactivation domain of FOXO1.
Via the PAX3 domains, the protein binds to more than one thousand
sites in the genome, mostly promoter-distal enhancer regions enriched
for PAX3 motifs [32] thereby causing transcriptional activation of
several hundred target genes. The target gene signature contains dif-
ferent myogenic as well as neuronal markers, reﬂecting the physiolo-
gical function of the wildtype PAX3 protein [27,33,34]. This also sup-
ports the hypothesis that the cell of origin of aRMS is a cell of the
myogenic lineage and that the fusion protein blocks terminal diﬀer-
entiation. Among the targets are also diﬀerent potentially druggable
proteins such as several receptor tyrosine kinases (FGFR2, FGFR4,
IGF1R, ALK, MET) and G-protein coupled receptors (CB1, ADRA2C) (for
a comprehensive review on PAX3-FOXO1 target genes see [35]).
Apart from the fusion proteins, the mutational landscape of aRMS
tumors is very quiet with an average of only 6.4 somatic mutations per
tumor, from which only 2.5 mutations (median) are in transcribed
genes. Again only a fraction of them are cancer-associated and drug-
gable [2]. Importantly however, genomic analyses mainly focused on
the coding part of the genome. In-depth analysis of the non-coding part
of the genome will be necessary to test for somatic mutations in reg-
ulatory regions that are involved in RMS tumorigenesis. Furthermore,
the involvement of inherited genetic changes needs more attention in
the future. Druggable proteins boosted by such genetic changes might
represent another class of potentially suitable targets. In the meantime,
druggable driver genes are available in only a small number of cases for
potential therapy. These include mutant PIK3CA (in about 2% of cases)
or ampliﬁed CDK4 (ampliﬁed in about 12% of cases) [2,36,37]. How-
ever, these mutations represent secondary hits that appear after gen-
eration of the translocation and therefore might be present only in
subclones of the tumor [3]. Furthermore, functional validation of CDK4
as therapeutic target in RMS revealed an inverse correlation between
CDK4 expression levels and sensitivity towards CDK4 inhibitors, sug-
gesting that therapeutic decisions cannot be based solely on genetic
information, but careful functional characterization of cellular de-
pendencies is an important prerequisite [38].
In contrast, diﬀerent studies have shown that human aRMS tumor
cells depend on continuous activity of the fusion protein [4,33,39].
Therefore, both from a genetic and functional point of view the PAX-
FOXO1 fusion proteins are the most promising targets in the large
majority of aRMS cases.
Along these lines, we summarize here the current knowledge re-
garding the diﬀerent layers of regulatory mechanisms of the PAX3-
FOXO1 fusion protein including modulators, co-regulators, and eﬀec-
tors and discuss their potential for therapeutic interventions (Fig. 1).
3. Mechanisms regulating PAX3-FOXO1 activity and their
potential for therapeutic intervention
3.1. Modulators
In general, modulators of fusion TFs include proteins involved in
synthesis and degradation pathways as well as proteins involved in
potential activation/inhibition mechanisms (Fig. 1). We will discuss
here these diﬀerent aspects of the fusion protein biology and compare
the mechanisms to the wild type proteins, if information is available.
Currently, not much is known about mechanisms controlling the
transcription of the fusion protein. While upstream enhancers that drive
PAX3 expression in the myogenic or neuronal lineage have been iden-
tiﬁed [40,41], their involvement in transcriptional control of the fusion
protein in aRMS cells remains to be investigated. However, it has been
reported that HDAC inhibition by Entinostat leads to decreased tran-
scription of the fusion protein and slows tumor growth in xenograft
experiments [42]. In addition to Entinostat, which has not entered the
clinical stage yet, also the clinically approved HDAC inhibitors Pano-
binostat and Vorinostat have been shown to aﬀect aRMS cell viability
[43]. However, since HDAC inhibitors might induce a complex com-
bination of downstream eﬀects, more research is needed to clarify the
order and interplay of events leading to reduction of PAX3-FOXO1
transcription and cell viability under these conditions.
More information is available about regulatory mechanisms ex-
erting their function at the post-translational level. A plethora of
modiﬁcation sites has been identiﬁed in wild type FOXO1 [44]. Many of
them are located in its C-terminal half and are therefore also present in
the fusion protein, including at least 29 phosphorylation, 8 acetylation,
2 methylation and 5 O-GlcNAc sites (Fig. 2) [44]. This indicates that a
complex enzymatic network is regulating FOXO1 activity. While many
of the modiﬁcations have only been detected by high throughput mass
spectrometry or after in vitro enzymatic assays [44] and are not yet
functionally validated, for several of these sites involvement in
Fig. 2. Scheme depicting posttranslational modiﬁcations and their potential inﬂuence on PAX3-FOXO1 function. The locations of the individual modiﬁed residues on the PAX3-FOXO1
sequence are indicated by vertical lines. Red and green lines indicate phosphorylation and acetylation sites detected in PAX3-FOXO1, respectively. Residues discussed in the text are
labeled above the illustration, together with involved enzymes and their role in PAX3-FOXO1 function. Black and purple lines indicate phosphorylation and acetylation sites detected in
PAX3 or FOXO1, respectively, but not (yet) in PAX3-FOXO1. PD, paired domain; OP, octapeptide; HB, homeodomain; BP, breakpoint; TA, transactivation domain.
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subcellular localization and degradation of FOXO1 could be shown.
Interestingly, among these are conserved AKT phosphorylation sites
(S437/S500 in PAX3-FOXO1) as well as sites phosphorylated by addi-
tional kinases that all regulate nuclear-export and proteasomal de-
gradation of FOXO1 (for a comprehensive review on this topic see
[45]). Importantly however, in context of the fusion protein the eﬀect
of these modiﬁcations on subcellular localization are overridden by a
strong nuclear localization signal present in the PAX3 domain [46] and
their potential physiological role remains to be demonstrated.
Indeed, regulation of degradation seems to be one major aspect that
diﬀers considerably between PAX3-FOXO1 and wildtype PAX3 and
FOXO1 proteins and this might contribute to the oncogenic eﬀect of the
fusion protein. First evidence for this came from diﬀerentiating as well
as proliferating myoblast cells where (exogenous) PAX3-FOXO1 was
shown to be more stable than both endo- and exogenous PAX3. The
diﬀerence has been assigned to a monoubiquitination site relevant for
proteasomal degradation, which is present in the C-terminal half of
PAX3 and therefore absent in the fusion protein [47,48]. However, also
PAX3-FOXO1 protein levels were subsequently shown to be under
control of the Ubiquitin-proteasome system since PAX3-FOXO1 levels
can be stabilized by proteasome inhibitors such as MG-132 in aRMS
cells [49–51]. Furthermore, endogenous PAX3-FOXO1 is able to de-
stabilize the TF EGR1 by a mechanism involving direct interaction and
subsequent co-degradation via the proteasome, from which it was
concluded that the fusion protein is relatively unstable in aRMS cells
[50,51]. Along these lines, several post-translational modiﬁcations have
been identiﬁed that might inﬂuence fusion protein stability. First,
phosphorylation by AKT at unknown sites was shown to inhibit the
activity of the fusion protein [52], and AKT activation via Thapsigargin-
treatment led to reduced DNA binding activity and subsequently to
degradation of the fusion protein in aRMS cells [53]. Second, in a
combined screening approach with both a kinome-wide siRNA library
and a large drug library containing mostly kinase inhibitors, PLK1 was
identiﬁed as a regulator of PAX3-FOXO1 protein stability [49]. Phos-
phorylation of Ser503 by PLK1 stabilizes the PAX3-FOXO1 protein and
its inhibition leads to rapid degradation of the fusion protein via the
proteasomal pathway. PLK1 expression is regulated in a cell cycle de-
pendent manner and increases from late S to M phase and its activity
peaks during mitosis. Since also transcription of PAX3-FOXO1 has been
shown to peak in G2 [54], PAX3-FOXO1 levels seem to be upregulated
during G2/M phase of the cell cycle by mechanisms acting both at the
mRNA and protein level. This upregulation has been linked with
checkpoint adaption, allowing the cell to transit the G2/M checkpoint
despite presence of unrepaired cellular damage [54], an eﬀect of PAX3-
FOXO1 with potential clinical implications taking into account that
DNA-damage induced cell cycle arrest and apoptosis is a central aim of
conventional chemo- and radiotherapy [54].
Interestingly, besides PLK1, diﬀerent other enzymes have been
shown to modify PAX3-FOXO1 in the same region. Among them is the
acetyltransferase KAT2B (P/CAF) which, via acetylation of two nearby
lysine residues (K426/K429), has also been shown to have a stabiliza-
tion eﬀect on PAX3-FOXO1 [55]. In wildtype FOXO1, acetylation of
these lysines stimulates phosphorylation of the nearby Ser256 (Ser437
in PAX3-FOXO1) [56] and subsequent nuclear export as well as Skp2-
mediated ubiquitination and degradation [57], again pointing to dif-
ferences between wild type FOXO1 and the fusion protein. Importantly,
genetic and pharmacological interference with both PLK1 (inhibitor
Volasertib) and P/CAF (inhibitor Embelin) reduced aRMS cell viability
in vitro and xenograft growth in mice, in case of Volasertib treatment
manifesting even as dramatic tumor regression [49,55].
Finally, CDK4 has been claimed to phosphorylate Ser430 in PAX3-
FOXO1 and its inhibition with Fascaplysin led to redistribution of the
fusion protein to the cytoplasm, thereby reducing its transcriptional
activity [58]. Whether the clinically approved CDK4/6 inhibitor Pal-
bociclib, which has been shown to inhibit aRMS cell proliferation in
vitro and to delay xenograft growth in mice [59], has similar eﬀects,
needs further clariﬁcation. Taken together, these data suggest that
modiﬁcations of the breakpoint-proximal region of the FOXO1 domain
might aﬀect localization and/or stability of PAX3-FOXO1 (Fig. 2).
Therefore, pharmacological induction of degradation might be a po-
tential approach for aRMS therapy. Further characterization of the
molecular mechanisms regulating PAX3-FOXO1 stability such as iden-
tiﬁcation of ubiquinated lysine residue(s) and components of the de-
gradation machinery (E3 ligases and de-ubiquinating enzymes) might
reveal additional important possibilities to pharmacologically enhance
degradation of the fusion protein.
Apart from protein stability, diﬀerent groups also described some
activation mechanisms of PAX3-FOXO1. One mechanism seems to in-
volve several phosphorylation events that take place in the PAX3 do-
main of the fusion protein (Fig. 2) [44]. Modiﬁed sites are located in the
conserved octapeptide region located between the two DNA binding
domains of both PAX3 and PAX3-FOXO1 [60–62]. The FDA-approved
kinase inhibitor PKC412 (Midostaurin) interferes with phosphorylation
in this region, an eﬀect which is accompanied by both eﬃcient induc-
tion of cell death and inhibition of PAX3-FOXO1 activity, at least at
some target genes [60]. While others have linked this region with
protein–protein interaction [63], it was shown that inhibition of
phosphorylation reduces DNA binding and consequently transactiva-
tion activity of the fusion protein [60]. Since PKC412, as derivative of
Staurosporine, aﬀects a broad spectrum of kinases, the identity of the
involved kinase(s) is not clear yet. However, the phosphorylated pep-
tide contains six potential phosphorylation sites, which are present in
the very regular order Ser187xxxxxSer193xxxSer197xxxSer201xxx-
Ser205xxxSer209. The motif SerxxxSer(P) represents a consensus
phosphorylation motif for the kinase GSK3 [64]. For eﬃcient phos-
phorylation by GSK3, the C-terminal Ser is normally phosphorylated by
a priming kinase. In some cases, such as the very similar 5-Ser motif
present in muscle glycogen synthase, this priming step is done by CK2
[65,66]. In agreement with such cooperation, phosphorylation of
wildtype PAX3 at Ser201 and Ser205 in myoblasts was found to depend
on GSK3 and CK2, respectively [61,62]. Furthermore, two recent pub-
lications showed that diﬀerent GSK3 inhibitors were able to reduce
phosphorylation of Ser201 in endogenous PAX3-FOXO1 and also to
aﬀect viability of aRMS cells [67,68]. This suggests that GSK3 indeed
could be (one of) the kinase(s) phosphorylating this peptide. Since
PKC412 as well as GSK3-inhibitors potentially interfere with cellular
physiology also at other levels, it is not clear yet to which extent re-
duction of PAX3-FOXO1 activity contributes to the induction of cell
death. Hence, further validation of these results is necessary before they
can potentially be applied as aRMS therapy. However, these ﬁrst ﬁnd-
ings identifying regulatory mechanisms aﬀecting PAX3 activity via
modulation of DNA binding may open the door for more speciﬁc ways
to interfere with fusion protein activity.
3.2. Co-regulators
While numerous interactors/co-regulators of the wildtype con-
tributors to the PAX3-FOXO1 fusion, particularly of FOXO1, have al-
ready been described [69], identiﬁcation of co-regulators of PAX3-
FOXO1 in aRMS cells was a rather neglected area of research. Only
recently, insights from few novel studies are now beginning to shed
some light on this.
In one of these studies, CHD4 has been identiﬁed as co-regulator of
PAX3-FOXO1 for a subset of its target genes and CHD4 silencing was
shown to eﬃciently induce aRMS cell death [70]. CHD4 is a multi-
domain protein containing two plant homeodomains (PHD), two
chromodomains and a SNF2-like ATPase domain, the latter deﬁning
this protein as a member of the ATP-dependent chromatin remodeling
protein family. Chromatin remodelers use the energy of ATP hydrolysis
to move, destabilize, eject, or restructure the nucleosomes in the
chromatin. Thereby they aﬀect packaging/accessibility of the DNA for
the molecular machineries involved in replication, repair as well as
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transcription. CHD4, like its homologues CHD3 and CHD5, is a per-
ipheral component of the Nucleosome Remodeling Deacetylase (NuRD)
complex [71]. Initially, this large complex was mainly associated with
transcriptional repression, but it is now appreciated that its eﬀects on
gene expression are more complex and can also include stimulation of
gene expression [72]. Interestingly, CHD4 was associated in diﬀerent
studies with an activating function of NuRD. In the neuronal lineage it
was shown that the identity of the CHD protein present in the NuRD
complex determines its inﬂuence on gene expression and cellular be-
havior [73]. In progenitors, CHD4 is a component of the NuRD com-
plex, induces expression of key regulators of neuronal development
such as PAX6 and SOX2 and promotes cell proliferation. The switch to
CHD5 and CHD3 at later developmental stages induces repression of the
very same genes and is associated with migration and diﬀerentiation of
the cells, respectively [73]. In agreement with this model is data from
mouse embryonic stem cells where CHD4 has been found to bind to the
−1 and +1 nucleosomes ﬂanking nuclear free regions (NFR) around
the transcriptional start site of a subset of active genes [74]. Im-
portantly, depletion of CHD4 resulted in reduction of RNA Polymerase
II (Pol II) levels at these sites, suggesting that presence of CHD4 is of
general importance for recruitment of the transcriptional machinery
[74]. The mechanisms by which CHD4 co-activates transcription of
PAX3-FOXO1 target genes in aRMS would also support these char-
acteristics [70] since CHD4 does not directly interact with PAX3-
FOXO1 but binds to sites in the chromatin located in close distance to
PAX3-FOXO1 occupied sites. Based on ChIP qPCR studies it was pos-
tulated that binding of CHD4 is necessary for subsequent landing of
PAX3-FOXO1, potentially allowing PAX3-FOXO1 to activate transcrip-
tion. A handful of other studies demonstrated similar collaborative in-
terplays of CHD4 with TFs such as GATA3 in T-helper 2 cells or CLOCK-
BMAL1 in mouse tissue [75,76]. On the contrary, CHD4 has also been
associated with repression of gene expression. In colorectal cancer cells,
it is involved in a DNA-damage response mechanism leading to general
transcriptional repression [77]. CHD4 is recruited via OGG1 and
ZMYND8 to sites of oxidative DNA damage and double strand breaks,
respectively. It co-recruits transcriptional repressor enzymes including
the DNA methyltransferases DNMT1, DNMT3A, and DNMT3 B as well
as the histone methyltransferases EZH2 and G9a. By depositing re-
pressive chromatin modiﬁcations e.g. in promoters of tumor suppressor
genes, this CHD4 complex promotes tumorigenesis [77,78]. The re-
levance of such repressive activity of CHD4 in aRMS cells, however, is
not clear yet. Nevertheless, taken together, these data highlight CHD4
as potential therapeutic target in aRMS aﬀecting PAX3-FOXO1 activity.
In another recent study, BRD4 was identiﬁed as co-regulator of
PAX3-FOXO1 [79]. BRD4 is a versatile activator of transcription at the
level of the chromatin. The protein has histone acetyltransferase (HAT)
activity involved in nucleosomal eviction and chromatin decompaction
at gene promoters as well as an atypical kinase activity phosphorylating
the C-terminal domain of Pol II, thereby regulating promoter pause-
release and transcriptional elongation [80,81]. The small molecule in-
hibitor JQ1 interferes with chromatin binding of BRD4 by blocking its
bromodomain, which normally recruits this protein to active genomic
sites with high histone acetylation levels. Although BRD4 occupies a
large part of all active regulatory elements in the genome, treatment
with JQ1 leads to preferential loss of BRD4 from the largest and most
active enhancers (“super-enhancers (SE)”)[82]. Since SE drive the ex-
pression of key oncogenes in many tumors, tumor cells often show an
enhanced sensitivity towards JQ1 [82,83]. In accordance with these
concepts, it was found in aRMS cells that BRD4 and PAX3-FOXO1
collaborate particularly at SE-driven target genes of the fusion protein.
Hence, JQ1 and other BRD4 inhibitors suppress a large part of the
target gene signature of PAX3-FOXO1 and induce death of aRMS cells in
vitro and tumor growth suppression in vivo. Mechanistically, BRD4 was
shown to interact with PAX3-FOXO1 and its inhibition by JQ1 leads to
depletion of both BRD4 and PAX3-FOXO1 from co-occupied genomic
sites as well as a dramatic reduction of the half-life of PAX3-FOXO1.
Apart from interference with the activity of PAX3-FOXO1 and poten-
tially other TFs, JQ1 has also been associated with inhibition of an-
giogenesis via direct eﬀects on endothelial cells in aRMS xenograft tu-
mors [84], suggesting that its tumor suppressive eﬀect is the result of
diverse mechanisms. Interestingly however, both CHD4 and BRD4 have
no inﬂuence on transcription of PAX3-FOXO1 itself, pointing at dif-
ferences in regulation of the fusion protein and its major downstream
targets.
From a conceptual point of view the outcome of blocking CHD4 or
BRD4 in aRMS cells seem to be very similar. For both their inﬂuence on
the transcriptome goes beyond fusion protein target genes. Ultimately,
inhibition might lead to induction of transcriptional chaos, which
drives cancer cells into a death program. Such eﬀects could be of
general signiﬁcance for transcription-addicted cancers [85]. Indeed,
available BRD4 inhibitors might be of therapeutic value in a range of
tumors, often associated with downregulation of driver oncogenes
[82,83]. Hence, BRD4 targeting is an already quite advanced approach
and ﬁrst clinical trials are ongoing. Also CHD4 blockade has been found
to aﬀect viability of a range of cancer types including breast and liver
cancer or AML [86–88]. However, in contrast to BRD4, no small mo-
lecule inhibitor for CHD4 is currently available. Importantly, some of
the CHD4 domains are potentially druggable including the PHD- and
the chromo-domains which mediate binding of the protein to un-
modiﬁed or H3K9-methylated histones and DNA, respectively [89] as
well as the helicase domain.
The inﬂuence of BRD4 and CHD4 as epigenetic regulators on PAX3-
FOXO1 activity and aRMS cell viability raise the important question
whether other epigenetic regulators have similar roles. Since many of
them are druggable, such proteins could be interesting targets as well
and more research in this area therefore holds a lot of promise.
3.3. Eﬀectors
The level of target genes is the most extensively studied aspect of
PAX3-FOXO1 biology during the last decade. A selection of PAX3-
FOXO1 target genes with inhibitors available was tested as targets for
therapy.
One type of target genes studied in this context are diﬀerent cell
surface receptors. Prime candidates are receptor tyrosine kinases
(RTKs) such as IGF1R, FGFR4, ALK and MET, for which small molecule
and/or antibody inhibitors are available. Inhibition of some of these
kinases indeed revealed promising eﬀects in preclinical models based
on cell lines [90–95]. However, experience with the IGF1R inhibitory
antibody R1507 in a phase II clinical study with Ewing and other sar-
coma dampened the enthusiasm for application of these inhibitors [96],
since the initial objective response rate of 10% was rather modest.
While careful selection of patients based on biomarkers for treatment
response might allow to increase this number, responses seen in sen-
sitive cases were also only transient. Intrinsic and acquired resistances
therefore play a major role and aﬀect treatment outcome. Some of the
resistance mechanisms involved were characterized later in in vitro
studies and involved stabilization of IGF1R, heterodimerization of
IGF1R with other receptor tyrosine kinases as well as activation of
parallel or downstream kinase signaling pathways [97–100]. Hence,
these data are in perfect agreement with the comprehensive experience
gained with such drugs during the last decade when used for the
treatment of carcinoma. There, it was learned that therapy responses
are mainly seen in cases where the target is activated by mutation or
gene ampliﬁcation and acts as a driver in the corresponding tumor,
such as in cases of BRAF V600E mutant melanoma or ERBB2/HER2-
ampliﬁed tumors [101]. However, even then outgrow of resistant re-
lapse tumors follows initial regression in virtually all cases. In aRMS
however, despite being highly overexpressed as targets of the fusion
protein, all the kinases discussed are usually wildtype and, with ex-
ception of ALK in some rare cases [102], not genetically ampliﬁed. This
further limits their potential as therapeutic targets. Most likely, such
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drugs should be used in combination with standard-of-care che-
motherapy or other targeted drugs.
Another type of receptor that was investigated in a similar way was
the cannabinoid receptor 1 (CB1) [103]. This was based on the ﬁnding
that diﬀerent tumors expressing high levels of CB1 including glioma,
breast cancer and melanoma are sensitive towards CB1-agonists
[104–106]. There, treatment with the natural cannabinoid Δ9-tetra-
hydrocannabinol (THC) or synthetic CB1-agonists lead to induction of
cell death. In many of these cancers, the mechanism behind this eﬀect
involves induction of de novo synthesis of the sphingolipid ceramide,
which via induction of ER stress ﬁrst stimulates autophagy and subse-
quently apoptotic cell death (for review see [107]). Indeed, the same
phenomenon was also detected in aRMS cells in vitro and in vivo [103].
Furthermore, CB1 inhibition also reduced lung metastasis formation in
a PAX3-FOXO1-overexpression myoblast model [108]. Similar to RTKs
however, activation of signaling pathways via overexpression of ALK or
activation of ERK has been found to lead to resistance towards CB1
agonists in several types of tumors, hence this treatment might be as-
sociated with the same downsides as discussed above for RTKs
[109,110].
A second type of target genes potentially suitable for therapeutic
purposes are regulators of the apoptotic machinery. An interesting
PAX3-FOXO1 target in this context is Bcl-XL [111]. This anti-apoptotic
protein of the Bcl-2 family is upregulated in many tumors and blocks
intrinsic apoptosis upstream of the mitochondria by neutralizing pro-
apoptotic Bcl-2 family members. Bcl-XL inhibition therefore shifts the
balance between these proteins towards induction of apoptosis. Im-
portantly, PAX3-FOXO1 was shown to also upregulate the pro-apoptotic
Bcl-2 family member NOXA in aRMS cells [112]. Potentially, this sets
the cells into a state referred to as “primed” for apoptosis, which makes
them especially amenable for apoptosis-directed drugs [113]. In
agreement with this hypothesis is data showing that the cytotoxic ef-
fects of a series of drugs in aRMS cells is mediated (at least partially) by
NOXA [112,114–117]. Diﬀerent inhibitors are available for Bcl-XL
targeting, with variable eﬀects on other anti-apoptotic Bcl-2 family
proteins. Their action might be especially useful in combination with
other drugs to enhance induction of apoptosis. Indeed, ABT737, an
inhibitor of Bcl-XL, Bcl-2 and Bcl-w, synergized with diﬀerent inhibitors
of the PI3 K/AKT/mTOR pathway in induction of apoptosis of aRMS
cells in vitro [118]. The clinical development of Bcl-XL inhibitors
however has been slowed down due to on-target induced thrombocy-
topenia [119,120], a side eﬀect that might be circumvented by ad-
justing dosing schedules [121].
Along the lines described above, a third class of interesting target
genes are epigenetic regulators, among them JARID2 [122]. JARID2
belongs to the Jumonji family of histone demethylases, however it lacks
some critical active site residues and therefore doesn‘t have demethy-
lase activity. Instead, it is thought to act as scaﬀold protein and to re-
cruit repressive epigenetic complexes like PRC2 or other methyl-
transferase complexes including G9a/GLP and SETDB1 to the
chromatin. Thereby it induces an increase of the repressive chromatin
marks H3K27me3 and H3K9me3 [123–125]. This then leads to tran-
scriptional silencing of the targeted genes. The core PRC2 complex is
composed of the three proteins SUZ12, EED and the methyltransferase
EZH2 or its close homologue EZH1. By orchestrating gene expression
changes, PRC2 is a central regulator of cellular diﬀerentiation including
the one along the myogenic lineage [126]. For proper muscle diﬀer-
entiation, a complex interplay between PRC2-EZH1 and PRC2-EZH2 at
muscle diﬀerentiation genes takes place. The PRC2-EZH2 complex is
removed while the PRC2-EZH1 complex is recruited to some muscle
diﬀerentiation factors such as MYOG, and both these steps are required
for activation of the early myogenic program via MYOD [127]. Most
PRC2 components including EED, SUZ12 and EZH2, but not EZH1, are
overexpressed in aRMS when compared to skeletal muscle cells
[122,128]. Hence, it has been suggested that PRC2-EZH2 contributes to
the undiﬀerentiated phenotype of aRMS by repressing diﬀerentiation
genes [122]. In accordance with this, it was shown that silencing of
JARID2 in aRMS cells leads to reduced levels of H3K27me3 at myogenic
diﬀerentiation genes including MYOG and MYL1 and induction of ex-
pression of these genes. Similar eﬀects were seen after silencing of EED
[122]. On the cellular level, JARID2 silencing leads to reduction of
proliferation and induction of a diﬀerentiation phenotype of aRMS
cells. Taken together, these data suggest that JARID2 mediates some of
the well-known anti-diﬀerentiation eﬀects of PAX3-FOXO1 in aRMS
cells, potentially via PRC2. Since diﬀerentiation therapy has been found
to be a successful approach in other tumors, most prominently in acute
promyelocytic leukemia [129], these data might stimulate further
evaluation of this form of therapy for aRMS. EZH2 is a druggable PRC2
component and diﬀerent EZH2 inhibitors are currently under clinical
development. Interestingly however, recent testing of the EZH2 in-
hibitor Tazemetostat by the pediatric preclinical testing program re-
vealed no relevant eﬀect on aRMS xenograft growth in mice [130].
Hence, deeper insights into epigenetic regulation of transcription are
required to see whether and which PRC2-directed drugs would be
suitable for aRMS diﬀerentiation therapy.
An important aspect that must be taken into account when inter-
preting the potential of downstream eﬀectors of PAX3-FOXO1 as ther-
apeutic targets is the fact that a physiological ranking of the diﬀerent
PAX3-FOXO1 target genes based on their relevance for tumorigenesis is
still missing at this point. Since only a small fraction of target genes
could be investigated so far and since the targets with highest relevance
might also be most eﬀective as targets for treatment, the most im-
portant ﬁndings in this area could still lie ahead.
4. Conclusions and perspectives
As outlined for PAX3-FOXO1 above, the biology of individual fusion
TFs is complex and a lot of eﬀort is needed to identify optimal strategies
to interfere with their activity. Furthermore, the large variety of fusion
TFs expressed by diﬀerent tumor entities or sometimes even in one
speciﬁc tumor type as well as rarity of many of these tumors complicate
functional studies and slow down the therapeutic progress. However,
diﬀerent molecular techniques developed during the past few years
may allow to address some important aspects of fusion TF biology in a
more eﬃcient way in the near future, therefore accelerating research. A
prominent example is CRISPR-Cas9 mediated genome editing, which
has developed into a plethora of downstream applications. Of special
interest for fusion TF research could be knock-ins of reporters into
target gene loci that can be used in genetic or pharmacologic screens to
evaluate fusion protein activity. Other CRISPR-Cas9 applications in-
clude library screens for identiﬁcation of the most relevant target genes
or generation of chromosomal translocations in potential cells of origin.
Further, CRISPR-Cas9 will also facilitate the generation of sophisticated
genetically engineered mouse models, which will allow mimicking the
human disease in more detail. Furthermore, connectivity maps might
help to ﬁnd drugs that aﬀect the PAX3-FOXO1 induced gene expression
program [131].
Also in the area of protein targeting recent developments might
open novel possibilities. One approach is targeting of proteins by drugs
that covalently bind to their target and do not rely on hydrophobic
binding pockets [15]. Another potentially useful method is the pro-
teolysis targeting chimera (PROTAC) technique used to induce speciﬁc
degradation of proteins. Basis for this technology are chimaeric small
molecules that combine a moiety that binds to the protein of interest
with a second one that binds to an E3 ligase, thereby inducing ubi-
quitination and degradation of the protein of interest. The PROTAC
technique was already described in 2001 [132], but early approaches
lacked potency [133]. Recently however, it was re-awakened as pro-
mising approach for cancer treatment. This was based on the ﬁnding
that a speciﬁc class of small molecules called Phtalimides, such as the
infamous teratogenic compound Thalidomide, bind to the E3 ligase
Cereblon and thereby establish a novel interface that leads to
M. Wachtel, B.W. Schäfer Seminars in Cancer Biology xxx (xxxx) xxx–xxx
6
recruitment and degradation of the transcription factors IKZF1/3 as
well as CK1α. This eﬀect is of therapeutic value in multiple myeloma
and myelodysplastic syndrome, respectively [134–137]. By coupling
Phtalimides with a second small molecule which speciﬁcally binds to a
protein of interest, Cereblon–mediated degradation of any target pro-
tein in Cereblon-positive cells might be induced [138]. Another pro-
mising E3 ligase that can be hijacked in a similar way for speciﬁc de-
gradation purposes is VHL [139,140]. Collectively, these techniques
have the potential to shift the paradigms of the (un)druggability of
fusion TFs and other proteins that are problematic to drug.
A potential alternative to genetically driven selection of therapies is
represented by the functional screening for unrecognized vulner-
abilities by direct drug-proﬁling of patient cancer cells. The most ad-
vanced protocols for such an approach involve transplantation of tumor
material from individual patients as patient derived xenograft (PDX)
into mice for ampliﬁcation of the tumor material. Secondary transplants
with the ampliﬁed tumor material can then be used for tests of (small
numbers) of drugs in vivo. For high-throughput screening with larger
drug libraries in vitro cultures of primary cells from PDX might be es-
tablished. Since not all tumors engraft in mice and since each engraft-
ment round normally takes one to several months of time, the optimal
solution would be the establishment of primary cell cultures, either in
2D or 3D, directly from the patient material in a co-clinical approach.
This approach however necessitates on the one hand suﬃcient amounts
of untreated tumor material and on the other hand culture conditions
preventing overgrowth of stromal cells such as ﬁbroblasts.
Despite all these promising novel techniques for target/drug iden-
tiﬁcation, a major therapeutic hurdle is the development of drug re-
sistance. Especially when applied as single agent, development of re-
sistance against targeted drugs is very often inevitable. Numerous
diﬀerent mechanisms have been described to be involved in therapy
resistance, including changes in drug metabolism or circumventing
dependency on the drug target (summarized in [141]). Concerning the
latter, loss of dependency on PAX3-FOXO1 was recently described in a
study using a human myoblast based aRMS model [142]. There, to
mimic aRMS development, myoblasts were transduced with doxycy-
cline-inducible PAX3-FOXO1 and MYCN. Cells expressing the two on-
cogenes were found to eﬃciently form xenograft tumors in mice. Fur-
thermore, silencing of PAX3-FOXO1 expression upon doxycycline-
withdrawal as expected induced tumor regression. Unexpectedly how-
ever, a minor population of cells in some of the established tumors was
found to survive PAX3-FOXO1 depletion and generate PAX3-FOXO1
negative relapse tumors [142]. Whether human aRMS tumors also
contain cells that are not PAX3-FOXO1-dependent however needs fur-
ther clariﬁcation. A common way to circumvent development of re-
sistance to therapy makes use of drug combinations, an approach that
was shown to be much less prone to develop therapy resistances [143].
PAX3-FOXO1 directed drugs in combination with standard-of-care
therapy might be an option to eradicate resistant cells upfront. In the
long run, the knowledge of diﬀerent molecular angles to interfere with
PAX3-FOXO1 activity however opens the possibility for combinations
of drugs that act at diﬀerent molecular levels.
Overall, the data reviewed here highlights that a period of genetic
analyses of the cancer genome, performed during the past two decades,
has facilitated the identiﬁcation of the drivers of tumorigenesis in nu-
merous tumors. Now a period of intense functional studies is necessary
to ﬁnd ways to interfere with these proteins. In case of oncogenic fusion
TFs, the exploration of the biological context could be one route to
zoom in on these diﬃcult to drug molecules and ﬁnd angles for a
therapeutic intervention. Another route might be opened by novel
protein targeting techniques. Approaches combining knowledge-based
drugs with functional drug proﬁling to identify unrecognized tumor
speciﬁc vulnerabilities might represent the most successful approaches
in the future.
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